Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5085168
Max Phase: Preclinical
Molecular Formula: C28H43NO29S
Molecular Weight: 889.70
Molecule Type: Unknown
Associated Items:
ID: ALA5085168
Max Phase: Preclinical
Molecular Formula: C28H43NO29S
Molecular Weight: 889.70
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NCCOCCO[C@@H]1O[C@@H](C(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@@H]3O[C@@H](C(=O)O)[C@@H](O[C@@H]4O[C@@H](C(=O)O)[C@@H](OS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
Standard InChI: InChI=1S/C28H43NO29S/c29-1-2-49-3-4-50-25-9(34)5(30)13(17(54-25)21(38)39)51-26-10(35)6(31)14(18(55-26)22(40)41)52-27-11(36)7(32)15(19(56-27)23(42)43)53-28-12(37)8(33)16(58-59(46,47)48)20(57-28)24(44)45/h5-20,25-28,30-37H,1-4,29H2,(H,38,39)(H,40,41)(H,42,43)(H,44,45)(H,46,47,48)/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,25-,26-,27-,28-/m1/s1
Standard InChI Key: CGLAJRHCOGSPRB-LVEVGGMOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 889.70 | Molecular Weight (Monoisotopic): 889.1641 | AlogP: -9.55 | #Rotatable Bonds: 18 |
Polar Surface Area: 483.73 | Molecular Species: ZWITTERION | HBA: 25 | HBD: 14 |
#RO5 Violations: 3 | HBA (Lipinski): 30 | HBD (Lipinski): 15 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: -2.09 | CX Basic pKa: 9.44 | CX LogP: -8.13 | CX LogD: -22.21 |
Aromatic Rings: 0 | Heavy Atoms: 59 | QED Weighted: 0.04 | Np Likeness Score: 0.71 |
1. Shanthamurthy CD, Leviatan Ben-Arye S, Kumar NV, Yehuda S, Amon R, Woods RJ, Padler-Karavani V, Kikkeri R.. (2021) Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development., 64 (6.0): [PMID:33683903] [10.1021/acs.jmedchem.0c01800] |
Source(1):